CancerNetwork® Inaugural Face-Off

home / face-off / cancernetwork-inaugural-face-off

In a new series from CancerNetwork®, two teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.

Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks

EP. 1: Team Introductions: The Moffitt Marrowvingians vs The Memorial Sloan-Kettering Mavericks

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Varun Narendra, MD;Xiaoli Mi, MD;Meghan Thompson, MD
May 6th 2022

Steven Frommeyer kicks off a new and exciting competitive series from CancerNetwork® and introduces the first 2 teams.

Use of Inotuzumab for ALL in the Frontline Setting

EP. 2: Use of Inotuzumab for ALL in the Frontline Setting

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD
May 6th 2022

Nikesh Shah, MD, presents a trial published in Lancet Oncology in 2018 on the use of inotuzumab plus mini-CVD in the frontline setting for older patients with ALL.

HyperCVAD in Frontline ALL

EP. 3: HyperCVAD in Frontline ALL

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Xiaoli Mi, MD;Varun Narendra, MD
May 13th 2022

Nikesh Shah, MD, explains a key trial evaluating the efficacy and toxicity of hyper-CVAD in acute lymphocytic leukemia (ALL).

Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists

EP. 4: Adoption of Pediatric-Inspired ALL Regimens by Adult Oncologists

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD
May 13th 2022

Reem Akel, MD, presents a population-based study on the adoption of pediatric-inspired acute lymphoblastic leukemia (ALL) regimens by adult oncologists.

Cross Q&A: Team Moffitt Marrowvingians

EP. 5: Cross Q&A: Team Moffitt Marrowvingians

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD
May 23rd 2022

The Memorial Sloan Kettering team gets the opportunity to question the clinical trial data presented by the H. Lee Moffitt team.

A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study

EP. 6: A Pediatric Regimen for Older Adults and Adolescents with ALL: CALGB 10403 Study

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD
May 23rd 2022

Varun Narendra, MD, presents the CALGB 10403 clinical trial on the use of a pediatric regimen in older adolescents and young adults with ALL.

Pediatric-Inspired Chemotherapy Incorporating Pegaspargase in Adults with Ph-ALL

EP. 7: Pediatric-Inspired Chemotherapy Incorporating Pegaspargase in Adults with Ph-ALL

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD;Reem Akel, MD
May 27th 2022

Varun Narendra, MD, describes a clinical trial that studied whether pediatric-inspired ALL regimens could be used in older adults with Philadelphia chromosome–positive ALL.

Outcome Determination for Adolescents and Young Adults with ALL

EP. 8: Outcome Determination for Adolescents and Young Adults with ALL

Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD;Xiaoli Mi, MD
May 27th 2022

Xiaoli Mi, MD, presents data from a paper in Blood on the determination of outcomes for adolescents and young adults with ALL.

Cross Q&A: The Memorial Sloan-Kettering Mavericks

EP. 9: Cross Q&A: The Memorial Sloan-Kettering Mavericks

Xiaoli Mi, MD;Steven Frommeyer;Nikesh Shah, MD;Somedeb Ball, MD;Reem Akel, MD;Meghan Thompson, MD;Varun Narendra, MD
May 27th 2022

The Moffitt Marrowvingians take their turn questioning the Memorial Sloan Kettering Mavericks on their presented clinical trial data.

Recap: Fellows at MSK and Moffitt ‘Face Off’ to Discuss Treatment Strategies in Older Patients With ALL

EP. 10: Recap: Fellows at MSK and Moffitt ‘Face Off’ to Discuss Treatment Strategies in Older Patients With ALL

ONCOLOGY Staff
July 4th 2022

In a new series from CancerNetwork®, 2 teams of fellows from leading institutions go head-to-head to debate the latest datasets and advances in acute lymphoblastic leukemia.